← All trials
NCT01484015
Phase 1Interventional
Includes initial studies to determine the metabolism and pharmacologic actions of drugs in humans, the side effects associated with increasing doses, and to gain early evidence of effectiveness; may include healthy participants and/or patients.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Feb 1, 2011
- Primary completion
- Jun 1, 2012
- Completion date
- Oct 1, 2012
- First posted
- —
- Last posted
- —
- Enrollment
- 70
- Arms / groups
- 2 / —
- Source
- AACT · pre-existing
Sponsors
- Wake Forest UniversityLead sponsor
- Wake Forest UniversityOverall official - principal investigator
- National Cancer Institute (NCI)Collaborator
Drugs studied
Indications studied
- Carcinoma, Ovarian Epithelial
- Breast Neoplasms
- Burkitt Lymphoma
- Hodgkin Disease
- Lymphoma, Follicular
- Lymphoma, Non-Hodgkin
- Multiple Myeloma
- Myelodysplastic Syndromes
- Myeloproliferative Disorders
- Neoplasm Metastasis
- Neuroblastoma
- Neutropenia
- Ovarian Neoplasms
- Sezary Syndrome
- Testicular Neoplasms
- Leukemia, Lymphocytic, Chronic, B-Cell
- Leukemia, Prolymphocytic
- Leukemia, Myelogenous, Chronic, BCR-ABL Positive
- Leukemia, Neutrophilic, Chronic
- Leukemia, Myeloid, Acute
- Leukemia, Eosinophilic, Acute
- Leukemia, Myelomonocytic, Chronic
- Lymphoma, Large-Cell, Immunoblastic
- Lymphoma, Large B-Cell, Diffuse
- Lymphoma, B-Cell, Marginal Zone
- Lymphoma, Mantle-Cell
- Precursor Cell Lymphoblastic Leukemia-Lymphoma
- Neoplasms, Plasma Cell
- Leukemia, Myeloid, Chronic, Atypical, BCR-ABL Negative
- Primary Myelofibrosis
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.